MA41120A - Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci - Google Patents

Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci

Info

Publication number
MA41120A
MA41120A MA041120A MA41120A MA41120A MA 41120 A MA41120 A MA 41120A MA 041120 A MA041120 A MA 041120A MA 41120 A MA41120 A MA 41120A MA 41120 A MA41120 A MA 41120A
Authority
MA
Morocco
Prior art keywords
hepe
treating
methods
compositions including
preventing fibrosis
Prior art date
Application number
MA041120A
Other languages
English (en)
Inventor
John Climax
Kevin Duffy
Jonathan Rowe
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of MA41120A publication Critical patent/MA41120A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA041120A 2014-12-02 2015-12-01 Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci MA41120A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462086535P 2014-12-02 2014-12-02

Publications (1)

Publication Number Publication Date
MA41120A true MA41120A (fr) 2017-10-10

Family

ID=56092410

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041120A MA41120A (fr) 2014-12-02 2015-12-01 Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci

Country Status (17)

Country Link
US (1) US10363235B2 (fr)
EP (2) EP3988101A1 (fr)
JP (2) JP6986445B2 (fr)
KR (1) KR20170102879A (fr)
CN (2) CN112245419A (fr)
AU (2) AU2015358512B2 (fr)
BR (1) BR112017011685A2 (fr)
CA (1) CA2968980A1 (fr)
ES (1) ES2900593T3 (fr)
IL (2) IL252431B (fr)
MA (1) MA41120A (fr)
MX (2) MX382116B (fr)
PH (1) PH12017501022B1 (fr)
RU (2) RU2020115523A (fr)
SG (2) SG10202010594WA (fr)
WO (1) WO2016090030A1 (fr)
ZA (2) ZA201704463B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
US10017453B2 (en) 2013-11-15 2018-07-10 Ds Biopharma Limited Pharmaceutically acceptable salts of fatty acids
AU2015204531B2 (en) * 2014-01-10 2019-11-14 Afimmune Limited Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same
HK1247136A1 (zh) * 2015-01-16 2018-09-21 Afimmune Limited 包含15-hepe的组合物和其使用方法
CN117402059A (zh) 2015-05-13 2024-01-16 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
KR20220038818A (ko) * 2015-12-18 2022-03-29 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
AU2634101A (en) * 2000-01-06 2001-07-16 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
EP1762557B1 (fr) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Mediateurs lipidiques actives par l'aspirine
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
EP1711173A2 (fr) 2003-12-31 2006-10-18 Igennus Limited Formulation contenant de l'acide eicosapentaenoique ou un ester de celui-ci et d'un triterpene ou un ester de celui-ci
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
EP3285072B1 (fr) * 2006-08-08 2020-04-15 Metabolon, Inc. Marqueurs de maladie du foie gras non alcoolique (nafld) et de la stéatohépatite non alcoolique (nash) et leurs procédés d'utilisation
US8042070B2 (en) * 2007-10-23 2011-10-18 International Business Machines Corporation Methods and system for analysis and management of parametric yield
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
WO2009154230A1 (fr) 2008-06-17 2009-12-23 持田製薬株式会社 Agent de prévention/amélioration ou de traitement de la stéatose hépatique non alcoolique
WO2010120880A1 (fr) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Traitement de maladies hépatiques avec un inhibiteur de caspase
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
WO2012135032A2 (fr) * 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Particules anti-inflammatoires
US20120264824A1 (en) * 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2013040316A1 (fr) * 2011-09-16 2013-03-21 Galectin Therapeutics, Inc. Utilisation d'une composition polysaccharidique de galactomannane pour traiter la stéatohépatite non alcoolique et la stéatose hépatique non alcoolique
US8936803B2 (en) 2011-10-19 2015-01-20 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
KR20140113921A (ko) 2011-11-29 2014-09-25 디그너티 사이언스 리미티드 20-탄소 지방산을 포함하는 조성물 및 이를 제조 및 사용하는 방법
BR112014014674A2 (pt) * 2011-12-16 2017-06-13 Tarix Pharmaceuticals Ltd angiotensinas para tratamento de fibrose
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
JP6370775B2 (ja) 2012-05-10 2018-08-08 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
TWI689489B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
KR20220038818A (ko) 2015-12-18 2022-03-29 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법

Also Published As

Publication number Publication date
ZA201704463B (en) 2018-11-28
PH12017501022B1 (en) 2022-02-16
CN107206008A (zh) 2017-09-26
MX2017007000A (es) 2017-12-07
IL252431A0 (en) 2017-07-31
IL252431B (en) 2021-12-01
EP3226873A1 (fr) 2017-10-11
AU2015358512A1 (en) 2017-07-20
AU2015358512B2 (en) 2021-02-18
RU2017122758A (ru) 2019-01-09
CA2968980A1 (fr) 2016-06-09
BR112017011685A2 (pt) 2018-01-02
EP3226873B1 (fr) 2021-10-27
MX382116B (es) 2025-03-13
ZA201804380B (en) 2021-03-31
CN112245419A (zh) 2021-01-22
RU2020115523A (ru) 2021-01-27
HK1245101A1 (zh) 2018-08-24
RU2017122758A3 (fr) 2019-06-13
EP3226873A4 (fr) 2018-08-08
JP6986445B2 (ja) 2021-12-22
US20160184252A1 (en) 2016-06-30
MX2021005080A (es) 2021-06-15
JP2017536380A (ja) 2017-12-07
AU2021203189A1 (en) 2021-06-10
PH12017501022A1 (en) 2017-11-27
IL287983A (en) 2022-01-01
JP2022031813A (ja) 2022-02-22
SG11201704495VA (en) 2017-06-29
RU2721555C2 (ru) 2020-05-20
EP3988101A1 (fr) 2022-04-27
US10363235B2 (en) 2019-07-30
KR20170102879A (ko) 2017-09-12
SG10202010594WA (en) 2020-12-30
WO2016090030A1 (fr) 2016-06-09
ES2900593T3 (es) 2022-03-17

Similar Documents

Publication Publication Date Title
EP3658612A4 (fr) Formation de particules comprenant des agents
EP3481434A4 (fr) Compositions à base de crispr/cas9 et méthodes de traitement de dégénérescences de la rétine
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
MA45192A (fr) Traitement d'association
EP3344274A4 (fr) Méthodes et compositions pour le traitement d'états pathologiques associés à des réponses inflammatoires anormales
ME03487B (fr) Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3324978A4 (fr) Compositions d'oligonucléotides et méthodes associées
EP3328376A4 (fr) Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
ME03070B (fr) Méthodes pour le traitement d'infections virales à filoviridae
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
EP3380095A4 (fr) Compositions et méthodes de traitement d'un avc ischémique
MA46750A (fr) Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents
EP3512524A4 (fr) Méthodes et compositions de traitement d'infections virales
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l'hyperhidrose
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
EP3317290A4 (fr) Compositions et méthodes de traitement d'une infection virale
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
EP3522865A4 (fr) Méthodes et compositions pour le traitement de vergetures
MA43106A (fr) Traitement de l'oligo-ovulation associée à la stéatose hepatique
EP3365014A4 (fr) Méthodes et compositions pour le traitement de la mastocytose systémique
EP3493823C0 (fr) Composé à base de postbiotique pour le traitement de l'inflammation oculaire